Arbutus Biopharma Corporation (ABUS) |
|
2.99 0.05 (1.7%)
|
03-17 16:00 |
|
Open: |
2.95 |
Pre. Close: |
2.94 |
|
High:
|
3.06 |
Low:
|
2.9191 |
|
Volume:
|
2,621,372 |
Market Cap:
|
486(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:43:23 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.59 One year: 4.2 |
| Support: |
Support1: 2.76 Support2: 2.56 |
| Resistance: |
Resistance1: 3.07 Resistance2: 3.59 |
| Pivot: |
2.88 |
| Moving Average: |
MA(5): 2.99 MA(20): 2.84
MA(100): 2.64 MA(250): 2.52 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 81.6  %D(3): 84.8 |
| RSI: |
RSI(14): 59.3 |
| 52-week: |
High: 3.22 Low: 1.85 |
| Average Vol(K): |
3-Month: 964 (K) 10-Days: 1,339 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABUS ] has closed below upper band by 23.9%. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.06 - 3.08 |
3.08 - 3.09 |
|
Low:
|
2.88 - 2.9 |
2.9 - 2.92 |
|
Close:
|
2.97 - 2.99 |
2.99 - 3.01 |
|
Company Description |
|
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. |
Headline News |
Sun, 19 Mar 2023
Those who invested in Arbutus Biopharma (NASDAQ:ABUS) three years ago are up 108% - Yahoo Finance UK
Thu, 16 Mar 2023
Arbutus Presents AB-343 Data at the 36th International Conference ... - MyChesCo
Thu, 16 Mar 2023
Arbutus Biopharma (ABUS) Doses First Subject in Phase 1 Clinical ... - StreetInsider.com
Fri, 10 Mar 2023
Moderna loses bid to shift liability in COVID-19 vaccine patent case - Reuters
Mon, 06 Mar 2023
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Sun, 05 Mar 2023
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Call Transcript - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
163 (M) |
| Shares Float |
120 (M) |
|
% Held by Insiders
|
25.6 (%) |
|
% Held by Institutions
|
33.3 (%) |
|
Shares Short
|
4,050 (K) |
|
Shares Short P.Month
|
4,310 (K) |
Stock Financials |
|
EPS
|
-0.47 |
|
EPS Est Next Qtl
|
-0.42 |
|
EPS Est This Year
|
-1.39 |
|
EPS Est Next Year
|
-1.36 |
|
Book Value (p.s.)
|
0.87 |
|
Profit Margin (%)
|
-178.1 |
|
Operating Margin (%)
|
-162.1 |
|
Return on Assets (ttm)
|
-19.8 |
|
Return on Equity (ttm)
|
-45.4 |
|
Qtrly Rev. Growth
|
94.8 |
|
Gross Profit (p.s.)
|
-0.28 |
|
Sales Per Share
|
0.24 |
|
EBITDA (p.s.)
|
-0.39 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-35 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-6.5 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.43 |
|
Price to Sales
|
12.45 |
|
Price to Cash Flow
|
-13.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
